Dolutegravir Sodium price

The development and launch of dolutegravir sodium represents an important milestone in antiretroviral therapy. The drug was developed by GlaxoSmithKline (GSK) and was first approved by the U.S. Food and Drug Administration (FDA) in 2013 for the treatment of HIV infection. It is also included in the list of preferred antiretroviral drugs recommended by the World Health Organization (WHO).

The working principle of dolutegravir sodium mainly relies on the inhibition ofHIVreverse transcriptase. Reverse transcriptase is an enzyme within the HIV virus. It is responsible for transcribing the virus's RNA into DNA so that it can be integrated into the genome of the host cell. Integration is a key step in the HIV replication process and is also a key link in HIV transmission. By inhibiting the activity of reverse transcriptase, dolutegravir sodium can prevent the integration of viral DNA into host cell DNA, thus blocking the replication of HIV.

The effectiveness and safety of dolutegravir sodium in antiretroviral therapy has been extensively studied and verified. Dolutegravir sodium has shown higher antiviral activity and lower risk of drug resistance development than some past antiHIVdrugs. This makes it an important part ofHIV treatment regimen.

Dolutegravir sodium has been launched in China, but it has not yet been included in medical insurance. Patients can purchase it in hospital pharmacies at a price of around 1,200 yuan. Please consult the local hospital pharmacy for specific prices. Dolutegravir sodium is cheaper abroad, mainly Indian generic drugs, with a price of around 350 yuan, and the ingredients of domestic original drugs and foreign generic drugs are basically the same.